Kawo Hankali: Shin Miligram 30 Zai Iya Yin Abu Daya da Miligram 10‑20?
Karin ashwagandha galibi ana siyar da su a cikin ɗaruruwan miligram. A wani sabon gwaji da aka wallafa a Phytotherapy Research (Prajapati da abokan aiki) an yi amfani da miligram 30 kacal a kowace rana. Kamar yadda aka nuna a taƙaitaccen bayani, wannan adadi ya isa don haɓaka VO2max idan aka kwatanta da placebo a cikin makonni takwas.
Kafin ka fara shirya ko sake tsarawa, ga abin da binciken ya nuna, abin da ya rage, da kuma wane irin mutane ne aka yi wa gwajin.
Abin Da Aka Gwada: Ba Kamar Kowane Ashwagandha Ba
Samfurin da aka yi amfani da shi ba shi ne “ɗanyen ashwagandha” na al'ada ba. Masu binciken sun zaɓi wani ƙaramin ƙarin ashwagandha (LDA) da aka yi masa alama da takardar Ashwa.30. Taƙaitaccen bayani ya bayyana shi a matsayin "cirewa daga tushe kawai kuma an inganta shi don ƙunshi sinadarai masu aiki" da aka daidaita zuwa:
- Withanolides: fiye da 15 % w/w
- "Bangaren ATP‑mai aiki": fiye da 15 % w/w
Wannan muhimmin ne: miligram 30 na nufin wannan takamaiman fitarwa da aka daidaita, ba kowace ƙwalba da ke ɗauke da alamar "ashwagandha" ba. Idan an sha miligram 30 na samfurin da ba a daidaita ba, sakamakon na iya bambanta, kuma binciken ba zai iya magana a kansa ba.
Tsarin Binciken
Gwajin ya kasance na makonni takwas, an raba mahalarta bazuwar, babu wanda yake gani, an gwada da placebo a tsakanin manyan lafiyayyun manya. Mahalarta sun karɓi ko dai 30 mg/LDA a kowace rana ko placebo.
- Manufar farko: VO2max – an ƙididdige ta ta hanyar Modified Bruce Protocol Treadmill Test (MBPTT).
- Manufar ta biyu: matakan lactic acid, creatine phosphokinase (CPK), Rating of Perceived Exertion (RPE), maki na gajiya a kan Visual Analog Scale (VAS), da alamu na lafiya.
Lambar VO2max an ƙididdige ta ne daga tsarin treadmill, ba a auna ta kai tsaye da na’urar gwajin iskar gas ba. Wannan hanya ce da ake yawan amfani da ita a aikace‑aikace, amma ba ta da daidaito kamar na gwaje‑gwajen dakin gwaje‑gwaje.
Babban Sakamako (Kamar Yadda Takaitaccen Bayani Ya Faɗa)
VO2max: LDA "ta haɓaka VO2max da kuma ƙarfin bugun zuciya sosai idan aka kwatanta da placebo." Takaitaccen bayani bai fitar da ƙididdigar da ta dace ba, don haka sai a duba cikakken takarda don ganin girman tasiri, matakin amincewa, da yawan mahalarta.
Gajiya: "Borg RPE da maki na gajiya sun inganta a rukunin LDA." Marubutan sun kammala da cewa ƙarin na taimakawa wajen "jinkirta fara gajiya."
Lactic acid: Rukunin da aka ba da magani ya nuna ƙananan matakan lactic acid a lokacin motsa jiki, abin da aka fassara a matsayin "dogon aikin aerobic."
CPK: Matakan CPK sun "yi ƙasa sosai," wanda marubutan suka danganta da "ƙarancin damuwar makamashi a tsokoki." CPK alama ce da ake danganta da gajiya ko rauni a tsokoki, amma takaitaccen bayani bai fayyace ko hakan ya haifar da sauƙin dawowa ko ƙasa da rauni ba. Ka ɗauki shi a matsayin wani alamar likita, ba matsayin tabbacin dawowa ba.
Tsaro: Abinda Takaitaccen Bayani Ya Nuna
LDA "ta jure sosai, ba tare da wani illa da ya danganci magani ba." Alamu na jini, hanta, kodar, da sauran alamu na metabolic sun kasance a cikin ƙima na al'ada. Wannan abu ne mai dadi ga manya masu lafiya a tsawon makonni takwas, amma ba ya nuni da sakamakon dogon lokaci a cikin al'umma.
Abubuwan Da Za A Iya Amfani Da Su
Kima: miligram 30 a kowace rana na wannan takamaiman fitarwa da aka daidaita – wato abin da aka yi amfani da shi a gwajin. Takaitaccen bayani bai gwada wasu ƙima ba, don haka ba zai iya gaya maka ko miligram 30 ya fi, ya dace da, ko ya rasa ƙima idan aka kwatanta da miligram 300‑600 ba. Ƙarin ƙima suna yawan bayyana a wasu binciken ashwagandha, amma wannan gwaji bai kwatanta su ba.
Tsawon lokaci: makonni takwas. Kada ka yi tsammani za ka ga canji nan take bayan ƙara ɗaya.
Lokacin shan magani: takaitaccen bayani bai bayyana ko an sha a safiya ko maraice ba. Ka duba cikakken rubutun maimakon zargin.
Wanda ya dace: Sakamakon ya shafi manya masu lafiya da ke son ƙara ƙarfin zuciya‑huhu da rage gajiya yayin motsa jiki. Marubutan sun bayyana shi a matsayin "mai aminci kuma tasiri a ƙaramin ƙima don ƙara juriya."
- Mahaɗin lafiya ko masu shan magani: Gwajin ya ƙunshi manya masu lafiya, don haka sakamakon ba ya rufe waɗanda ke da cututtuka ko ke shan magunguna. Ka tuntuɓi likita idan kana da ciki, matsalar thyroid, hanta, autoimmune, ko kana shan wasu magunguna.
- Masu neman babban ƙaruwa a wasan: Ba tare da ƙididdiga a takaitaccen bayani ba, "mai muhimmanci" yana nufin an samu bambanci a matakin ƙididdiga, ba cewa canjin ya kasance babba ba.
- Wanda ke siyan samfurin ashwagandha daban: Sakamakon ya ta'allaka ne ga wannan takamaiman fitarwa da aka daidaita.
Hanyoyin Masana'antu da Ƙuntatawar Sa
Takaitaccen bayani bai fayyace tushen kuɗi ko rikice‑rikicen sha'awa ba. Fitarwar tana nuni da wani samfurin alama (Ashwa.30), kuma gwaje‑gwajen kari na alama galibi sukan haɗa da kamfanin da ya kera shi. Wannan dalili ne da ya sa ya kamata a duba cikakken takardar nazari don sanin cikakken bayani, ba wata shaida ta son kai ba.
Wasu ƙuntatawa da ya kamata a tuna:
- Gwaji ɗaya ne kawai, kuma takaitaccen bayani bai ba da adadin mahalarta ba.
- VO2max an ƙididdige shi a kaikaice.
- Makonni takwas a cikin manya masu lafiya ba su ba da cikakken haske game da amfani na dogon lokaci ko a kan 'yan wasa masu ƙwarewa.
- Babu kwatancen kai tsaye da ƙarin kashi na ashwagandha.
Karshe
Miligram 30 na wani fitarwa na ashwagandha da aka daidaita, mai tsantsar tushe kawai, ya haɓaka VO2max da alamu na gajiya idan aka kwatanta da placebo a tsawon makonni takwas, ba tare da wani illa da ya danganci magani ba. Wannan sakamakon yana da ban sha'awa ga duk wanda ke tunanin ƙara miligram zai ƙara fa'ida. Sai dai har yanzu yana bukatar a sake gwadawa, tabbatar da masu zaman kansu, da nazarin cikakken bayanin gwaji da ƙididdiga don tantance haɗarin da ke iya tasowa kafin a ɗauke shi a matsayin babban sauyi.
Source: Prajapati et al., "Efficacy and Safety of Low‑Dose Ashwagandha Supplementation on Exercise Endurance: A Randomized, Placebo‑Controlled, Double‑Blind, Clinical Trial," Phytotherapy Research. DOI: 10.1002/ptr.70178. PubMed: https://pubmed.ncbi.nlm.nih.gov/41846233/